210095-55-9

Basic information

• Product Name: (R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine
• CAS NO: 210095-55-9
• Molecular Weight: 302.804
• Mol File: 210095-55-9.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: (R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine(210095-55-9)
• EPA Substance Registry System: (R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine(210095-55-9)

Safety Data

• Hazardous Substances Data: 210095-55-9(Hazardous Substances Data)

Usage

Description

(R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine is a complex chiral organic compound characterized by its unique three-dimensional structure. It features a pyridine ring, a piperidine ring, and a 4-chlorophenyl group, which may contribute to its potential pharmacological properties. The presence of the piperidine ring, a common structural motif in many pharmaceutical drugs, and the 4-chlorophenyl group suggests that this compound could have specific biological activities and be a valuable tool for drug discovery and development.

Uses

Used in Pharmaceutical Industry:
(R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine is used as a potential candidate for drug discovery and development due to its complex molecular structure and the presence of pharmacologically relevant groups such as the piperidine ring and the 4-chlorophenyl group. Its chiral nature also makes it an interesting subject for further research into its potential therapeutic applications.
Used in Research and Development:
(R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine serves as a valuable tool in the research and development of new therapeutic agents targeting specific biological pathways. Its unique molecular structure and chiral properties make it a promising compound for exploring novel drug mechanisms and potential treatments for various diseases.
Further research is necessary to fully understand the potential uses and effects of (R)-(+)-2-((4-chlorophenyl)(piperidin-4-yloxy)methyl)pyridine, as well as to determine its suitability for specific applications in the pharmaceutical and medical fields.

Upstream product

• 4045-22-1 N-acetyl-4-hydroxypiperidine 
• 142404-69-1 2-[chloro(4-chlorophenyl)methyl]pyridine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 122368-54-1 4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidine 
• 104-88-1 4-chlorobenzaldehyde 
• 109-04-6 2-bromo-pyridine 
• 27652-89-7 (4-chlorophenyl)-2-pyridylmethanol 
• 78539-93-2 3-(4-chlorophenyl)-[1,2,3]triazolo[1,5-a]pyridine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 207726-35-0 4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine-1-carboxylic acid ethyl ester 
• 125602-71-3 [14C]-Bepotastine besilate 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 180695-79-8 tert-butyl 4-bromo-1-piperidinecarboxylate 
• 176022-47-2 (S)-(+)-(4-chlorophenyl)-(2-pyridyl)methanol 

Downstream Products

• 1092777-18-8 (S)-bepotastine L-menthyl ester N-benzyloxycarbonyl-L-aspartate 
• 1560797-70-7 (S)-4-{4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino}butyric acid D-menthyl ester L-tartrate 
• 1560797-69-4 (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid D-menthyl ester 
• 1560797-78-5 (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid D-menthyl ester 
• 125602-71-3 Bepotastine 
• 125602-71-3 [14C]-Bepotastine besilate 
• 1560797-65-0 (RS)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid D-menthyl ester 
• 210095-48-0 ethyl (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid fumaric acid salt 

Relevant articles and documents

Total synthesis method of bestatin

The method comprises the following steps: (4 - chlorophenyl) (2 - pyridyl) - methanol as a starting raw material, and sequential addition reaction. Examples of the etherification reaction include a deprotection reaction, a chiral resolution, a condensation reaction, a hydrolysis reaction, and the like. The synthesis method has the advantages of cheap and easily available raw materials, no need of expensive chiral catalysts, simpler synthesis method, mild conditions, less side reactions and low cost.

Characterization of Photodegradation Products of Bepotastine Besilate and In Silico Evaluation of Their Physicochemical, Absorption, Distribution, Metabolism, Excretion and Toxicity Properties

Bepotastine (BPT) is a H1-receptor antagonist. It is used as a besilate salt in ophthalmic solution for allergic conjunctivitis and orally for the treatment of allergic rhinitis and urticaria/pruritus. Its systematic forced degradation study is unreported. The same was carried out in different conditions prescribed by International Conference on Harmonisation. The stressed solutions were subjected to reversed phase liquid chromatographic analysis, and BPT was observed to be labile under photobasic condition only, yielding 5 photodegradation products. The structures of the latter were elucidated from data generated by liquid chromatography–high-resolution mass spectrometry and multistage mass spectrometry. Of the 5, 4 products were further isolated and subjected to nuclear magnetic resonance spectroscopy to justify the proposed structures. Two of them, with similar accurate mass, were additionally and unambiguously characterized from their heteronuclear multiple bond correlation data, hydrogen deuterium exchange mass data, and quantum chemical analysis using density functional theory calculations. One degradation product had a structure that could only be explained by unusual rearrangement involving conversions of N-oxide into hydroxylamine, similar to Meisenheimer rearrangement. The physicochemical, as well as absorption, distribution, metabolism, excretion, and toxicity properties of BPT and its characterized photodegradation products were evaluated in silico by ADMET Predictor software.

Preparation method of important intermediate of bepotastine

The invention discloses a preparation method of an important intermediate of bepotastine. The preparation method is used for preparing (S)-(-)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine. The preparation method comprises that a racemate ((+/-)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine) and S-binaphthylphosphate undergo a reaction to produce a salt, the salt is dissociated by an alkali, and the dissociated salt is beat to form slurry of (S)-(-)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine. The (S)-(-)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine has optical purity of 99.0% or more. The disclosed chiral resolution method is simple, has a good industrial production prospect, and has a great significance for the industrial production of bepotastine.